REGN Regeneron Pharmaceuticals Inc.

392.66
+0.86  (+0%)
Previous Close 391.8
Open 391.42
Price To Book 4.9
Market Cap 42908781033
Shares 109,277,189
Volume 235,026
Short Ratio
Av. Daily Volume 712,199

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

FDA Approval announced September 28, 2018.
Cemiplimab
Cutaneous squamous cell carcinoma
FDA Approval announced August 17, 2018.
EYLEA
Wet AMD
sBLA Approval announced April 25, 2017.
Praluent (alirocumab)
High low-density lipoprotein (LDL) cholesterol
Phase 3 data due 4Q 2019.
Dupixent (dupilumab)
Atopic dermatitis 6-11 year-olds
FDA approval announced March 11, 2019.
Dupixent (dupilumab)
Atopic dermatitis 12-17 year-olds
PDUFA date for sBLA filing April 28, 2019.
Praluent (alirocumab) ODYSSEY OUTCOMES
Cardiovascular events
FDA approval announced October 19, 2018.
Dupixent (dupilumab)
Asthma
Pivotal Phase 2/3 trial ongoing.
REGN2810
Cutaneous squamous cell carcinoma
Phase 3 enrolling. Data due 2021.
Cemiplimab
Non-small cell lung cancer (NSCLC)
Phase 3 enrolling.
REGN2810
Non-small cell lung cancer (NSCLC)
Data due 2020.
Cemiplimab
Basal cell carcinoma
Phase 2 enrolling as of September 2017. BLA filing due 1Q 2018 pending data.
REGN2810
Basal cell carcinoma
Phase 3 trial met co-primary endpoints - August 16, 2018. Low dose arms only.
Fasinumab
Moderate-to-severe osteoarthritis pain of the hip or knee
Phase 3 data released August 14, 2017 - primary endpoint not met.
REGN2222
Respiratory syncytial virus (RSV)
PDUFA date for sBLA May 13, 2019.
EYLEA - PANAROMA
Nonproliferative Diabetic Retinopathy
Phase 3 ongoing.
EYLEA - PROTOCOL-W
Diabetic Retinopathy
Phase 3 enrollment commenced 2Q 2017. Data due 2021.
Dupixent (dupilumab)
Asthma - 6-11 year-olds
PDUFA date under priority review June 26, 2019.
Dupixent (dupilumab)
Nasal polyps
Phase 2b placed on clinical hold. Phase 3 trial to be initiated that excludes patients with advanced osteoarthritis 2H 2017.
Fasinumab
Osteoarthritis and chronic low back pain
Phase 2 data released November 27, 2017 - insufficient efficacy shown to warrant further development.
EYLEA + nesvacumab
Diabetic macular edema (DME)
Phase 2 data released November 27, 2017 - insufficient efficacy shown to warrant further development.
EYLEA + nesvacumab
AMD - age-related macular degeneration
Phase 2 trial to commence 2018.
Dupixent (dupilumab)
Peanut Allergy
Phase 3 trial commenced September 2018.
Dupixent (dupilumab)
Eosinophilic esophagitis
Approved under priority review - March 28, 2017.
Dupixent (dupilumab)
Atopic dermatitis
CRL October 28, 2016. Resubmitted with FDA Approval announced May 22, 2017.
Sarilumab
Rheumatoid arthritis
Phase 2 trial to commence 1H 2019.
REGN1979
Follicular Lymphoma
Phase 3 data due 2019.
Evinacumab (ANGPTL3 Antibody)
Homozygous familial hypercholesterolemia (HoFH)

Latest News

  1. Recent Analysis Shows Mastercard, Halliburton, Keysight Technologies, Eli Lilly, Wabash National, and Regeneron Pharmaceuticals Market Influences — Renewed Outlook, Key Drivers of Growth
  2. Better Buy: Vertex Pharmaceuticals vs. Regeneron Pharmaceuticals
  3. Biogen shares tank nearly 30% after pulling key Alzheimer’s drug trial
  4. Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
  5. See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc.
  6. Regeneron, Sanofi Get EC Nod for Label Expansion of Praluent
  7. Inovio's Early/Mid-Stage Vaccine Pipeline Exhibits Growth
  8. Dermira Investors Get 100% One-Day Payoff a Year After Acne Flop
  9. Praluent® (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease
  10. Try These 3 Steps To Compound Your Profits In The Best Growth Stocks
  11. 10 Stocks Powering S&P 500 ETF in the 10-Year Bull Run
  12. Biotech Stock Roundup: REGN Gets FDA Nod for Dupixent & Other Pipeline News
  13. Inovio (INO) Misses on Q4 Earnings & Revenues, Shares Down
  14. Regeneron and Sanofi to Present New Praluent® (alirocumab) Data at ACC.19
  15. Inovio Pharmaceuticals (INO) Q4 2018 Earnings Conference Call Transcript
  16. Teen Scientists Win $1.8 Million at Regeneron Science Talent Search 2019 with Innovative Ideas on Exoplanets, HIV and a Classic Math Problem
  17. Regeneron/Sanofi's Dupixent Gets FDA Nod for Label Expansion
  18. FDA Approves Dupixent® (dupilumab) for Moderate-to-severe Atopic Dermatitis in Adolescents
  19. Regeneron/Sanofi wins U.S. approval for expanded use of skin drug